Kiadis Pharma
Zernikepark 6-8
Groningen
9747 AN
Tel: 31-0-50-547-42-70
Fax: 31-0-50-547-42-71
Website: http://www.kiadis.com/
Email: info@kiadis.com
78 articles about Kiadis Pharma
-
Kiadis Pharma Presents Positive Data From A Pre Specified Interim Analysis Of The Phase 2 Clinical Program With Its Lead Product ATIR
12/9/2014
-
Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation By European Medicines Agency For The Treatment Of Acute Myeloid Leukemia
10/30/2014
-
Kiadis Pharma Appoints Jeroen Rovers As Its Chief Medical Officer
9/3/2014
-
Kiadis Pharma Initiates Collaboration For Personalized Immunotherapies Using ATIRTM With Technische Universitat Munchen Within Munich Biotech Cluster
1/29/2014
-
Kiadis Pharma Participates In Haploidentical Transplantation 2013 Forum
12/5/2013
-
Kiadis Pharma Provides Positive Update On Its Phase II Clinical Program With Blood Cancer Treatment ATIR™
11/18/2013
-
Kiadis Pharma Secures Manufacturing Services Agreement for Its Phase II Clinical Program With Blood Cancer Treatment ATIR With the German Red Cross Blood Donor Service
10/7/2013
-
Kiadis Pharma Secures Manufacturing Services Agreement for Its Phase II Clinical Program With Blood Cancer Treatment ATIR™ With the German Red Cross Blood Donor Service
10/7/2013
-
Kiadis Pharma Completes Five-Year Follow-up of Its Phase I/II Clinical Study With Blood Cancer Product ATIR™ and Study Meets Primary Objective
9/11/2013
-
Kiadis Pharma to Receive GMP Manufacturing License and GMP Certificate
7/23/2013
-
Kiadis Pharma Awarded a €3 Million Innovation Credit From the Dutch Government for Phase II Clinical Development Program
6/26/2013
-
Kiadis Pharma Receives Regulatory Approval From Health Canada for a Phase II Clinical Study With Its Blood Cancer Treatment ATIR
2/26/2013
-
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR
1/22/2013
-
Kiadis Pharma Raises $12.8 Million in Financing Round
11/20/2012
-
Kiadis Pharma Signs License Agreement with Hospira, Inc. to Commercialize ATIR(TM) in Europe and Asia
1/4/2011
-
Kiadis Pharma Receives IND Approval From FDA to Start Pivotal Clinical Trial With ATIR(TM) in the United States
7/8/2010
-
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) ATIR(TM) for Reduction of Transplant Related Mortality Following an Allogeneic Stem Cell Transplantation Using a Mismatched Donor
11/30/2009
-
Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations ATIR(TM) Data Presented at the Annual EBMT Presidential Symposium
4/8/2009
-
Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
1/6/2009
-
Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
12/8/2008